|
1
|
Japanese Society for Cancer of the Colon
and Rectum: Multi-institutional registry of large bowel cancer in
Japan, cases treated in 1995–1998.
17:1999.18:2000.21:2001.24:2003.
|
|
2
|
Heald RJ, Husband EM and Ryall RD: The
mesorectum in rectal cancer surgery - the clue to pelvic
recurrence? Br J Surg. 69:613–616. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shah SA, Haddad R, Al-Sukhni W, Kim RD,
Greig PD, Grant DR, Taylor BR, Langer B, Gallinger S and Wei AC:
Surgical resection of hepatic and pulmonary metastases from
colorectal carcinoma. J Am Coll Surg. 202:468–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar
|
|
5
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G,
Landi B, Colin P, Louvet C and de Gramont A: FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study. J Clin Oncol. 22:229–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, Couture F, Sirzén F and Cassidy J: Bevacizumab in
combination with oxaliplatin-based chemotherapy as first-line
therapy in metastatic colorectal cancer: a randomized phase III
study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bosset JF, Collette L, Calais G, Mineur L,
Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier
JC: EORTC Radiotherapy Group Trial 22921: Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med.
355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M and Bedenne
L: Preoperative radiotherapy with or without concurrent
fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD
9203. J Clin Oncol. 24:4620–4625. 2006.PubMed/NCBI
|
|
9
|
Tsukagoshi S, Hashimoto Y, Fujii G,
Kobayashi H, Nomoto K and Orita K: Krestin (PSK). Cancer Treat Rev.
11:131–155. 1984. View Article : Google Scholar
|
|
10
|
Araya S, Nio Y, Hayashi H, Masai Y,
Tsubono M, Ishigami S and Imamura M: Various plant-derived
polysaccharides augment the expression of HLA on Colo205 human
colonic cancer line. J Jpn Soc Cancer Ther. 29:1965–1973. 1994.
|
|
11
|
Hirose K, Zachariae CO, Oppenheim JJ and
Matsushima K: Induction of gene expression and production of
immunomodulating cytokines by PSK in human peripheral blood
mononuclear cells. Lymphokine Res. 9:475–483. 1990.PubMed/NCBI
|
|
12
|
Algarra I, Collado A, Garcia Lora A and
Garrido F: Differential effect of protein-bound polysaccharide
(PSK) on survival of experimental murine tumors. J Exp Clin Cancer
Res. 18:39–46. 1999.PubMed/NCBI
|
|
13
|
Harada M, Matsunaga K, Oguchi Y, Iijima H,
Tamada K, Abe K, Takenoyama M, Ito O, Kimura G and Nomoto K: Oral
administration of PSK can improve the impaired anti-tumor
CD4+ T-cell response in gut-associated lymphoid tissue
(GALT) of specific-pathogen-free mice. Int J Cancer. 70:362–372.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Torisu M, Hayashi Y, Ishimitsu T, Fujimura
T, Iwasaki K, Katano M, Yamamoto H, Kimura Y, Takesue M, Kondo M,
et al: Significant prolongation of disease-free period gained by
oral polysaccharide K (PSK) administration after curative surgical
operation of colorectal cancer. Cancer Immunol Immunother.
31:261–268. 1990. View Article : Google Scholar
|
|
15
|
Sakamoto J, Morita S, Oba K, Matsui T,
Kobayashi M, Nakazato H and Ohashi Y; Meta-Analysis Group of the
Japanese Society for Cancer of the Colon Rectum: Efficacy of
adjuvant immunochemotherapy with polysaccharide K for patients with
curatively resected colorectal cancer: a meta-analysis of centrally
randomized controlled clinical trials. Cancer Immunol Immunother.
55:404–411. 2006. View Article : Google Scholar
|
|
16
|
Ohwada S, Ikeya T, Yokomori T, Kusaba T,
Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S,
Ishikawa H, Kawate S, Nakajima T and Morishita Y: Adjuvant
immunochemotherapy with oral Tegaful/Uracil plus PSK in patients
with stage II or III colorectal cancer: a randomized controlled
study. Br J Cancer. 90:1003–1010. 2004. View Article : Google Scholar
|
|
17
|
Yoshitani S and Takashima S: Efficacy of
postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly
patients with resected colorectal cancer. Cancer Biother
Radiopharm. 24:35–40. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shibata M, Nezu T, Fujisaki S, Andou K,
Tomita R and Fukuzawa M: Clinical potential of biological response
modifiers combined with chemotherapy for gastric cancer. Japanese
experience Dig Surg. 19:255–260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oba K, Teramukai S, Kobayashi M, Matsui T,
Kodera Y and Sakamoto J: Efficacy of adjuvant immunochemotherapy
with polysaccharide K for patients with curative resections of
gastric cancer. Cancer Immunol Immunother. 56:905–911. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ogoshi K, Satou H, Isono K, Mitomi T,
Endoh M and Sugita M: Immunotherapy for esophageal cancer. A
randomized trial in combination with radiotherapy and
radiochemotherapy Cooperative Study Group for Esophageal Cancer in
Japan. Am J Clin Oncol. 18:216–222. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morimoto T, Ogawa M, Orita K, Sugimachi K,
Toge T, Dohi K, Nomura Y, Monden Y and Ogawa N: Postoperative
adjuvant randomised trial comparing chemoendocrine therapy,
chemotherapy and immunotherapy for patients with stage II breast
cancer: 5-year results from the Nishinihon Cooperative Study Group
of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of
Japan. Eur J Cancer. 32A:235–242. 1996.
|
|
22
|
Hayakawa K, Mitsuhashi N, Saito Y,
Nakayama Y, Furuta M, Nakamoto S, Kawashima M and Niibe H: Effect
of Krestin as adjuvant treatment following radical radiotherapy in
non-small cell lung cancer patients. Cancer Detect Prev. 21:71–77.
1997.PubMed/NCBI
|
|
23
|
Sato T, Yamaguchi A, Goi T, Hirono Y,
Takeuchi K, Katayama K and Matsukawa S: Heparanase expression in
human colorectal cancer and its relationship to tumor angiogenesis,
hematogenous metastasis and prognosis. J Surg Oncol. 87:174–181.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goi T, Yamaguchi A, Nakagawara G, Urano T,
Shiku H and Furukawa K: Reduced expression of deleted colorectal
carcinoma (DCC) protein in established colon cancers. Br J Cancer.
77:466–471. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fisher M and Yang LX: Anticancer effects
and mechanisms of polysaccharide-K (PSK): implications of cancer
immunotherapy. Anticancer Res. 22:1737–1754. 2002.PubMed/NCBI
|
|
26
|
Asai H, Iijima H, Matsunaga K, Oguchi Y,
Katsuno H and Maeda K: Protein-bound polysaccharide K augments IL-2
production from murine mesenteric lymph node CD4+ T
cells by modulating T cell receptor signaling. Cancer Immunol
Immunother. 57:1647–1655. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kato M, Hirose K, Hakozaki M, Ohno M,
Saito Y, Izutani R, Noguchi J, Hori Y, Okumoto S, Kuroda D, et al:
Induction of gene expression for immunomodulating cytokines in
peripheral blood mononuclear cells in response to orally
administered PSK, an immunomodulating protein-bound polysaccharide.
Cancer Immunol Immunother. 40:152–156. 1995. View Article : Google Scholar
|
|
28
|
Kobayashi H, Matsunaga K and Oguchi Y:
Antimetastatic effects of PSK (Krestin), a protein-bound
polysaccharide obtained from basidiomycetes: an overview. Cancer
Epidemiol Biomarkers Prev. 4:275–281. 1995.PubMed/NCBI
|
|
29
|
Hosokawa M, Mizukoshi T, Sugawara M and
Kobayashi H: Therapeutic effects of PS-K and busulfan on the
recurrent and metastatic diseases after the surgical removal of
3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice.
Jpn J Cancer Res. 76:61–67. 1985.
|
|
30
|
Fidler IJ and Ellis LM: The implications
of angiogenesis for the biology and therapy of cancer metastasis.
Cell. 79:185–188. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heino J and Käpylä J: Cellular receptors
of extracellular matrix molecules. Curr Pharm Des. 15:1309–1317.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kramer JM: Basement membranes. WormBook.
1:1–15. 2005.
|
|
33
|
van der Flier A and Sonnenberg A: Function
and interactions of integrins. Cell Tissue Res. 305:285–298.
2001.
|
|
34
|
Paschos KA, Canovas D and Bird NC: The
role of cell adhesion molecules in the progression of colorectal
cancer and the development of liver metastasis. Cell Signal.
21:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
|
